Mettler-Toledo International Inc. Dividend History (MTD)
Mettler-Toledo International Inc. does not pay dividends currently 😔
They might in the future, check back soon!
About Mettler-Toledo International Inc.
Mettler-Toledo International Inc. is a global leader in precision instruments and services for various applications, including laboratory, industrial, and food retailing. Founded in 1945, the company has grown to become a trusted name in measurement technology, offering a wide range of products such as weighing instruments, analytical applications, and process analytics equipment. Headquartered in Columbus, Ohio, Mettler-Toledo operates in over 100 countries, ensuring a strong global presence. As of the latest available information, the CEO is Patrick Kaltenbach. The company is renowned for its innovative solutions and commitment to quality, boasting impressive annual revenues exceeding $3 billion. With a focus on accuracy and reliability, Mettler-Toledo continues to serve diverse industries, supporting their needs with cutting-edge technology and expertise.
Agilent Technologies, Inc.
Bio-Rad Laboratories, Inc.
Bruker Corporation
Danaher Corporation
IQVIA Holdings Inc.
PerkinElmer, Inc.
Thermo Fisher Scientific Inc.
Waters Corporation
The global sample preparation market is expected to grow at a CAGR of 6.4% by 2031, driven by technological advancements in specimen collection and preparation. The consumables segment and solid-phase extraction technique are expected to lead the market growth.
Benzinga · Published on Mon Dec 02 2024
The article discusses the potential impact of President Trump's policies on the stock market in 2025, noting that while a corporate tax rate cut could boost earnings, the growing deficit may make further tax cuts difficult. The author suggests the stock market's performance may not match the economic growth under the Trump administration.
Investing.com · Published on Mon Dec 02 2024The global viral inactivation market is expected to grow from $653.8 million in 2023 to $1915.2 million by 2033, driven by increased investments in the life sciences industry and the need for better biopharmaceutical treatments. However, challenges related to the inactivation process may impede market growth.
GlobeNewswire Inc. · Published on Thu Sep 05 2024